Get the Stockscreener App
9.79
0.72%
0.07
Pre-market:
9.88
0.09
+0.92%
Zevra Therapeutics Inc stock is traded at $9.79, with a volume of 597.98K.
It is up +0.72% in the last 24 hours and down -1.90% over the past month.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
See More
Previous Close:
$9.72
Open:
$9.75
24h Volume:
597.98K
Relative Volume:
0.58
Market Cap:
$574.79M
Revenue:
$106.47M
Net Income/Loss:
$82.89M
P/E Ratio:
6.5546
EPS:
1.4936
Net Cash Flow:
$-2.43M
1W Performance:
+1.14%
1M Performance:
-1.90%
6M Performance:
-6.67%
1Y Performance:
+40.26%
1-Day Range:
$9.68
$9.86
1-Week Range:
$9.35
$10.02
52-Week Range:
$6.7701
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(888) 958-1253
Address
101 FEDERAL STREET, BOSTON
Compare ZVRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
9.79 | 556.00M | 106.47M | 82.89M | -2.43M | 1.4936 |
VRTX
Vertex Pharmaceuticals Inc
|
444.28 | 110.97B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
755.51 | 79.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
828.35 | 49.73B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
339.41 | 42.98B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
310.00 | 34.37B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Initiated | BTIG Research | Buy |
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Short Squeeze: Will Zevra Therapeutics Inc benefit from geopolitical trendsMarket Performance Summary & Free Verified High Yield Trade Plans - baoquankhu1.vn
Moving Averages: Can Zevra Therapeutics Inc maintain sales growth2026 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn
ZVRA SEC FilingsZevra Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Published on: 2026-04-10 05:39:10 - baoquankhu1.vn
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Returns Recap: Should I add Zevra Therapeutics Inc stock to my portfolioMarket Performance Report & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Stratos Wealth Partners LTD. Boosts Stake in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (NASDAQ: ZVRA) posts $106.5M 2025 revenue; proxy items - Stock Titan
ZVRA Technical Analysis | Trend, Signals & Chart Patterns | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra shares jump after selling SDX portfolio for $50M - MSN
(ZVRA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA - marketbeat.com
Zevra Therapeutics Inc (1GDA.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
ZVRA PE Ratio & Valuation, Is ZVRA Overvalued - Intellectia AI
ZVRA Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics Earnings Call Signals Profitable Turn - The Globe and Mail
Zevra Therapeutics Inc (1GDA.HM) interactive stock chart - Yahoo Finance UK
Sentiment Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Dividend Watch: Is Zevra Therapeutics Inc forming bullish engulfing patternsWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Zevra Therapeutics Inc (1GDA.HM) stock historical prices and data - Yahoo Finance UK
Vanguard realignment: affiliates to report ZVRA holdings separately (ZVRA) - stocktitan.net
John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K - Benzinga
How (ZVRA) Movements Inform Risk Allocation Models - Stock Traders Daily
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? - Yahoo Finance
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - MSN
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4) - MarketScreener
Zevra Ties NPC Testing Push To Valuation Gap And New CFO - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-03-21 14:23:45 - baoquankhu1.vn
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone - Sahm
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
GeneDx (WGS), Zevra Therapeutics (ZVRA) partner to launch sponsored genetic testing program for NPC - MSN
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC - Yahoo Finance
New Zevra finance chief gets a 300,000-share stock option - Stock Titan
Zevra Therapeutics announced that, in accordance with Nasdaq Listing Rule 5635(C)(4), it has granted an inducement equity award to the company's new Chief Financial Officer. - Bitget
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant - Stock Titan
Zevra Therapeutics (ZVRA) CFO Justin Renz files insider ownership report - Stock Titan
Zevra Therapeutics appoints Justin Renz as CFO - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook - Investing.com Nigeria
R. LaDuane Clifton (ZVRA) files Form 144 showing 11,000‑ and 3,000‑share sales - Stock Titan
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million and Settles Delaware Lawsuit 1 - Minichart
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpStill a Buy? - MarketBeat
Zevra Therapeutics Agrees to Sell SDX Portfolio to Commave Therapeutics for $50 Million - marketscreener.com
Zevra Shares Jump After Selling SDX Portfolio For $50M - Benzinga
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - markets.chroniclejournal.com
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook By Investing.com - Investing.com Australia
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research - MarketBeat
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):